Hypothyroidism Is a Risk Factor for New-Onset Diabetes: A Cohort Study

OBJECTIVE To identify risk factors for the development of statin-associated diabetes mellitus (DM). RESEARCH DESIGN AND METHODS The study was conducted in two phases. Phase one involved high-throughput in silico processing of a large amount of biomedical data to identify risk factors for the development of statin-associated DM. In phase two, the most prominent risk factor identified was confirmed in an observational cohort study at Clalit, the largest health care organization in Israel. Time-dependent Poisson regression multivariable models were performed to assess rate ratios (RRs) with 95% CIs for DM occurrence. RESULTS A total of 39,263 statin nonusers were matched by propensity score to 20,334 highly compliant statin initiators in 2004–2005 and followed until the end of 2010. Within 59,597 statin users and nonusers in a multivariable model, hypothyroidism and subclinical hypothyroidism carried an increased risk for DM (RR 1.53 [95% CI 1.31–1.79] and 1.75 [1.40–2.18], respectively). Hypothyroidism increased DM risk irrespective of statin treatment (RR 2.06 [1.42–2.99] and 1.66 [1.05–2.64] in statin users and nonusers, respectively). Subclinical hypothyroidism risk for DM was prominent only upon statin use (RR 1.94 [1.13–3.34] and 1.20 [0.52–2.75] in statin users and nonusers, respectively). Patients with hypothyroidism treated with thyroid hormone replacement therapy were not at increased risk for DM. CONCLUSIONS Hypothyroidism is a risk factor for DM. Subclinical hypothyroidism-associated risk for DM is prominent only upon statin use. Identifying and treating hypothyroidism and subclinical hypothyroidism might reduce DM risk. Future clinical studies are needed to confirm the findings.

[1]  G. Paragh,et al.  Effect of thyroid hormone status and concomitant medication on statin induced adverse effects in hyperlipidemic patients. , 2014, Die Pharmazie.

[2]  Kristian B Filion,et al.  Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases , 2014, BMJ : British Medical Journal.

[3]  Sangeeta Maity,et al.  Hyperthyroidism causes cardiac dysfunction by mitochondrial impairment and energy depletion. , 2013, The Journal of endocrinology.

[4]  M. Hernán,et al.  Statins and Risk of Diabetes , 2013, Diabetes Care.

[5]  L. Mascitelli,et al.  Do Statins Cause Diabetes? , 2013, Current Diabetes Reports.

[6]  H. Bundgaard,et al.  Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. , 2013, Journal of the American College of Cardiology.

[7]  L. Rallidis,et al.  Managing the underestimated risk of statin-associated myopathy. , 2012, International journal of cardiology.

[8]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[9]  A. Klip,et al.  Triiodothyronine acutely stimulates glucose transport into L6 muscle cells without increasing surface GLUT4, GLUT1, or GLUT3. , 2012, Thyroid : official journal of the American Thyroid Association.

[10]  B. Casey,et al.  Relationship of Subclinical Thyroid Disease to the Incidence of Gestational Diabetes , 2012, Obstetrics and gynecology.

[11]  E. Pearce Update in lipid alterations in subclinical hypothyroidism. , 2012, The Journal of clinical endocrinology and metabolism.

[12]  J. Manson,et al.  Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. , 2012, Archives of internal medicine.

[13]  J. Turk,et al.  Mitochondrial Dysfunction and β-Cell Failure in Type 2 Diabetes Mellitus , 2011, Experimental diabetes research.

[14]  D. Eizirik,et al.  Bcl-2 proteins in diabetes: mitochondrial pathways of β-cell death and dysfunction. , 2011, Trends in cell biology.

[15]  Vassilis Virvilis,et al.  Literature mining, ontologies and information visualization for drug repurposing , 2011, Briefings Bioinform..

[16]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[17]  A. Persidis,et al.  Drug repurposing and adverse event prediction using high‐throughput literature analysis , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[18]  M. Pletcher,et al.  Statin therapy in young adults: ready for prime time? , 2010, Journal of the American College of Cardiology.

[19]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[20]  J. Kvetny,et al.  Subclinical Hypothyroidism Affects Mitochondrial Function , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[21]  G. Koren,et al.  The safety of metoclopramide use in the first trimester of pregnancy. , 2009, The New England journal of medicine.

[22]  V. Koshkin,et al.  Molecular and Metabolic Evidence for Mitochondrial Defects Associated With β-Cell Dysfunction in a Mouse Model of Type 2 Diabetes , 2009, Diabetes.

[23]  Joachim Spranger,et al.  A high normal TSH is associated with the metabolic syndrome , 2009, Clinical endocrinology.

[24]  T. Economopoulos,et al.  Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. , 2009, European journal of endocrinology.

[25]  W. Feeman Statin-fibrate combination therapy. , 2008, The American journal of cardiology.

[26]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[27]  M. Surks,et al.  Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. , 2007, Archives of internal medicine.

[28]  P. Venditti,et al.  Role of mitochondria in exercise-induced oxidative stress in skeletal muscle from hyperthyroid rats. , 2007, Archives of biochemistry and biophysics.

[29]  B. Wolffenbuttel,et al.  Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. , 2007, The Journal of clinical endocrinology and metabolism.

[30]  D. Panagiotakos,et al.  Insulin action in adipose tissue and muscle in hypothyroidism. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  L. Siculella,et al.  Hypothyroidism down-regulates mitochondrial citrate carrier activity and expression in rat liver. , 2006, Biochimica et biophysica acta.

[32]  H. Mabuchi,et al.  Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. , 2005, Journal of atherosclerosis and thrombosis.

[33]  L. Chamberlain Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3‐L1 adipocytes , 2001, FEBS letters.

[34]  S. Weinstein,et al.  Regulation of GLUT2 glucose transporter expression in liver by thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. , 1994, Endocrinology.

[35]  Rajesh,et al.  Higher Potency statins and the risk of new diabetes: multicentre, observational study of administrative databases , 2014 .

[36]  M. Schott Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH) , 2009 .